| |
IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management.
|
|
Today’s Big NewsMay 14, 2024 |
| By Gabrielle Masson AbbVie has inked a pact with Gilgamesh Pharmaceuticals aimed at developing next-gen therapies for psychiatric disorders. |
|
|
|
By Nick Paul Taylor Novo Nordisk is coming for Roche’s Hemlibra. A phase 3 trial of the Danish drugmaker’s challenger to the blockbuster hemophilia drug hit its primary endpoint, clearing the path for a filing for approval around the end of the year. |
By Max Bayer Sands Capital has raised a $555 million fund, bringing the total amount of committed life science-specific cash to $1.3 billion. The entire firm manages more than $54 billion across public and private bets. |
By Helen Floersh While success for prenatal cell therapies has so far been limited to a handful of case studies, every failure brings the science one step closer to translation. That progress comes with ethical concerns. |
|
Identify more unique genes with a rapid workflow (< 5 hrs) and inputs down to 1 ng. Explore the data.
|
|
By Angus Liu When Bayer unveiled a restructuring in January, the company didn't provide specifics on the number of planned job cuts. Now, the size of the initial round of cuts shows that CEO Bill Anderson means business. |
By Angus Liu Facing potential sanctions from the Department of Defense and a recent allegation that it had transferred a U.S. client's data to Beijing without consent, WuXi AppTec is again rebutting claims of its ties with Chinese authorities. |
By Conor Hale The agency has scheduled an advisory panel meeting May 23 to help evaluate the company’s Shield test, which is seeking an in vitro diagnostic approval for screening people ages 45 and up. |
Fierce podcastsDon’t miss an episode |
| | This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today! Sponsored by: Sengenics Corporation LLC |
| Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
